Management of Epstein-Barr Virus (EBV) Reactivation after Allogeneic Stem Cell Transplantation by Simultaneous Analysis of EBV DNA Load and EBV-Specific T Cell Reconstitution | Zendy

Nicola Annels | Zendy; Jayant Kalpoe | Zendy; Robbert G. M. Bredius | Zendy; Eric C. J. Claas | Zendy; Aloys C.M. Kroes | Zendy; Andrew D. Hislop | Zendy; D. van Baarle | Zendy; R. Maarten Egeler | Zendy; Maarten J. D. van Tol | Zendy; Arjan C. Lankester | Zendy

Open Access

Management of Epstein-Barr Virus (EBV) Reactivation after Allogeneic Stem Cell Transplantation by Simultaneous Analysis of EBV DNA Load and EBV-Specific T Cell Reconstitution

Author(s) -

Nicola Annels,

Jayant Kalpoe,

Robbert G. M. Bredius,

Eric C. J. Claas,

Aloys C.M. Kroes,

Andrew D. Hislop,

D. van Baarle,

R. Maarten Egeler,

Maarten J. D. van Tol,

Arjan C. Lankester

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/503838

Subject(s) - medicine , immunology , transplantation , epstein–barr virus , lymphoproliferative disorders , t cell , stem cell , viral load , asymptomatic , virus , b cell , virology , antibody , lymphoma , immune system , biology , genetics

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation and may progress to life-threatening lymphoproliferative disease (EBV-LPD) in the absence of adequate EBV-specific T cell immunity. Quantification of EBV DNA load in asymptomatic individuals who are at risk is a useful (although not entirely predictive) indicator of progression to EBV-LPD and guide for preemptive treatment with CD20 antibodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research